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Abstract
Objective: To review the current state ofpharmacological treatment ofdelirium in the
pediatric population and to derive a treatment protocolfrom our review.
Method: Medl ine-assisted search ofthe literature. Articlespertaining to the pharmacologi-
cal treatment qfdelirium in children and adolescents were reviewed. Due to thepaucity ofarticles,
studies qf treatment guidelinesfor delirium in the adult population were reviewed. A lsopresented
.for reference, are studies qfoptimal dosing regimens ofpsychotrophic agents potentially useful in
treating pediatric delirium. Our protocol is extrapolatedfrom previously established guidelinesfor
adult treatment meshedwith the current knowledgepresented in the literaturepertaining tochildren
and adolescents.
Results: Review revealed only one retrospective study evaluating the pharmacological
treatment qfdelirium in children and adolescents. One anecdotal report qfrisperidone successfully
treating delirium is presented. Intravenous haloperidol is the mainstay of pharmacological
treatment in medically ill adults and haloperidol hasa long historyqfsqfety and ifJicacy in children
and adolescents.
Conclusion: Use cfintraoenous haloperidol with titration to an efficacious dose would bethe
fi rst line approach to treat symptoms ofdelirium in the pediatric population. However the lack qf
data and systematic analysis in the literature demonstrates an acute needfo r structured research in
this area.
T he a im of th is art icle is to review th e curre nt sta te of pharm acological
trea tment of delirium in th e pedi at ric populat ion and to derive a treatment protocol
from our review. There is a conspicuous lack of research in th is area a nd th ere a re no
pr evio us reviews in th e lite ra tu re. To com ple te our obj ecti ve, we pr esent th e curre n t
sta te of treatment of delir ium in adults , along with th e limited a mo unt of lit eratu re
pertaining to delirium in child re n and adolescen ts . For referen ce, curre nt pedia tric
pharmacolo gical dosing regimen s a re presented . Our protocol is deri ved from an
ex t ra pola t ion of guid elin es for ad ult trea tment mesh ed with th e curre n t kn owledge
pr esented in th e li terat ure pertaining to child re n a nd ad olescents.
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Delirium is a transient m ental synd ro me of ac u te onse t, characterized by global
impairment of cog nit ive fun ct ion s, a re d uced level of consciousness, attentional
abnormalities, changes in psych omotor ac t ivity a nd a di sord ered sleep-wake cycle (I ).
The conce pt of d elirium has been recogni zed for approximate ly 2500 years (2). Th e
di agnostic crite r ia have evo lved to several co re featu res (Table 1) coupled with
specifie rs th at distinguish e t iology, i.e . du e to a general medica l condition, du e to
multiple e t iolog ies, for substance intox icat ion, for substance withdrawal and causes
not othe rwise specifie d (3).
The ave rage preval en ce of deliriu m in the ge ne ra l hos pi tal popu lation is 20% (4).
Althou gh the pediatric popula ti on has no t been well stud ied , Antoon e t a l. (5)
reported that a pproximate ly 14% of hospitali zed burn pat ients had delirium. These
es t imates may be low give n th at the re is a high rate of m isdiagnosis with d elirium.
Armstron g e t a I., (6) rep ort ed that 46% of hospit ali zed adu lts with de lirium were
mi sdi agn osed , i.e, a d eliriou s patient was di agn osed wit h anot her condition (de pres -
sive di sorder, psychotic di sorder , no diagnosis, etc.). Also th e expre ssion of delirium in
child re n can vary from adult s, e.g. magical thinking, mania or regression (7), making
the di agnosis eve n more difficult for the treati ng p hys icians . T he t ransi ent nature of
d elirium also adds to the difficulty with di agnosis.
The conseq ue nces of a ltered co nsc iousness can be qui te d el et erious to th e
patient, e .g. pulling ou t ca the te rs a nd ot he r se lf-inj urious be havior and has been
shown in ad ult populations to increase mortality (4 ,8) . Thus, ea r ly recognition of th e
de lir ium with approp ria te treatment is essen tial.
The fir st s te p in t he treatment of d eli riu m is to identi fy any ca us a l cond it ion.
The mo st com mo n ca uses involve intox ication wit h exogenous substances, syst emic or
ce re bral di sease a nd withd ra wa l from substances of abuse ( I) . However th e underly-
ing e tio logy may not be eas ily di stingu ish ed . T his ca n be q uite difficult in that th e
deli riu m may be ca used by multiple e tiolog ies and ind ividuall y may not be conside re d
sig nifica nt by th e treating ph ysicians. In the interi m of di agn osti c work-up, treatment
sho uld include reassurance a nd reorientation. If thi s is not su ffici ent, pharmacologi-
ca l intervention is used as an adj unc t for symptom management and antipsychotic
m ed ication has been th e main st ay of treatment (9) .
TABLE 1.
Diagnostic Criteria for Delirium
A) Disturbance of consciousness (i.e., reduced clar ity of awareness of the environment)
with reduced abilit y to focus, susta in, or shift attentio n.
B) A cha nge in cognition (such as memory deficit , disorientat ion, language distur-
bance) or th e developm ent of a perceptual disturb ance that is not bett er accounted
for by a preexist ing condition, established, or evolving dementia.
C) Th e disturbance develops over a short period of time (usually hours to days) and
tends to l1uctuat e during the course of th e day.
Diagnostic and Stati stical Manu al of Mental Disorders, Fourt h Edition . Washington, DC,
American Psychiatric Association, 1994.
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Haloperid ol, a butyrophenone neuroleptic that can be adm in ist er ed via enteral,
intramusc ular or intravenous rou tes, is a well-documented safe treatment of deliriu m
symptoms in adults (9). It is a high pot ency neuroleptic with low pot ential for
anticholin ergic , antialpha-adrenergic a nd autonomic effec ts and is unlikely to exacer-
bate delirium (9, 10). It all eviates ag gr ession, psychom ot or ag ita t ion, hallucinat ions
a nd delusions (10) and is cons ide re d th e preferred age nt for treating deli rium in the
cr it ica lly ill adult (II) . The intravenous route has a sa fe side -e ffect profile a nd has a
reduced incid en ce of ex trapyram idal rea cti ons when compa red to ora l adm inistration
( 10,12) . The intravenous rout e is also th e quickest way to initiate treatment , i.e. peak
serum levels are reach ed soon after administ ra t ion, whereas th e ente ra l a nd 1M
rou tes may take up to several hours ( 10). Also , parental dos es of haloperidol have
100% bioavailabi lity (compared to th e approximat e 60% bioavailabil ity of oral
dosing) , and are dos ed approxima te ly one- ha lf that of ora l doses ( 10). Initial bolus
intraven ou s dos es range from 0.5 to 20 mg (4) and mega-d oses (> 1000 mg/day) hav e
been given safely in cases of refractory delirium ( 13,14). Specific gu ide lines for
treating th e delirious adult patient vary in th e lit e rature. Sha piro et a l. ( I I) out line a
sta r ting dose of 2 to 10 mg intraven ously with th e dosage rep eat ed every 2 to 4 hI'S.
Maint enance dosing regimen s have been proposed of continuing int raven ous haloperi-
dol at 50% of th e dose th at contro lled sympto ms wit h rapid dose reduction ( 15) or
adm iniste ring low dose (0.5 to 3 mg) ora l ha lop eridol ( 16).
Antipsychotic medi cations though commonly pr escribed to child re n a rc not as
well investigat ed. The Food a nd Drug Administration (FDA) ad vertisin g guide lines
for halope ridol indi cat e use in (i) man agem ent of psych osis, (ii) contro l of t ics and
voca l utt eran ce in Tourette 's disorder, (iii) seve re behavioral probl ems in chi ldr en
marked by combativen ess a nd/or explosive hyperexcit abl e beh avior (tha t is not
accountable to immediate provications) a nd sho rt- te rm treat ment of ADHD (17) .
The lower age limit is 3 yea rs with dose limits of 0.15 rug/kg/day for psychosis and
0.075 rug/kg/d ay for beh avior disorders an d T ourett e 's disorder ( 17). However, review
of the lit erature by Findling et al. ( 18) reveal s th at halop eridol has a lso been used in
trea ting mood di sorders, pervasive developm ental disorder, mental ret a rdat ion,
conduct disorder, anorexia nervosa a nd person ality disorders in child re n a nd ado les-
cents. Chi ldren hav e been found to respond to lower neuroleptic plasm a levels ( 19)
a nd th e dosing of haloperidol, in th e pedi atric population , tends to be lower and more
conse rva t ive than in adults . The average optimal dose range of halope ridol for th e
schizophre nic ped iatric population is 0.02 to 0.12 mg/kg/day [0.5 to 3.5 rug/day] (20).
The most com mon sho rt-te rm side effec ts of hal op eridol in chi ldren an d adoles-
ce n ts are sedat ion a nd extra pyra midal sympto ms (E PS) (2 1). EPS are ra re ly obs erved
in pr esch ool-aged child re n, but a re mo re com mo n in schoo l age and adolesc ents (19).
The seda t ion is dose-rel at ed a nd ca n be reli eved by a reducti on in dose (21).
Extrapyramidal sym ptoms are not dose-d ependent a nd a re sudde n in onse t (9). Most
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EPS ca n be resolved with a reducti on in dose a nd/o r managem ent with a n ticholiner-
gics (20). Also, with sho rt -term haloperidol use, th e possibility of neurolept ic malig-
nant syndro me (NIVlS) should be conside red . NMS is a potent iall y fa tal complica t ion
that occurs at all ages a nd sta r ts within a few days of initiati ng neuroleptic treatmen t.
Fortunately th e synd ro me is rare - 0.4% to 0.5% of newly t rea ted patients (22). Also
of conce rn, in crit ica lly ill adults, is an association of prolonga t ion of th e QTc in terva l
(QT interval corrected for heart rate) with t he possib ility of e nsuing tor sad es de
pointes (a polymorphous ve nt ricula r tach ycardia) with in traven ou s butyroph en one
th erapy (23,24) . Lawren ce & Nas raway (23) recommen d e lec t roca rd iog ra m (E KG)
monitoring in crit ically ill patients, with discont inuation or redu ct ion of dose if th e
QTc interval len gthen s by 25% or more ove r baseline. Cardiac conduc t ion abnor ma li-
ti es associated with butyrophenone administ ra t ion in child re n a nd ado lescents ha ve
not been reported in th e lit erature and the implication s of thi s possibl e adverse effect
are not known.
There has onl y been on e study revealed in our sea rch th at address ed th e use of
neuroleptics to treat delirium in child re n a nd ad olescents. Brown et al. (25) studied
th e use of haloperidol in 30 pedi atric burn patients to treat ag ita t ion a nd delirium.
H ere th e short term use of haloperidol (longest peri od of treatment was three
months) had a n incid en ce of adve rse react ion s of 0.4 7% (a n episode of decr ea sed
consc ious nes s and a n episode of hypot en sion after 429 doses administ ered ). The
mean dose of haloperidol used was 0.047 mglk g wit h th e mean numb er of doses given
at 14. The largest cumula t ive dose administ ered over a 24-hour period was 0.455
mglk g. The la rgest number of doses given ove r a 24-hour period was six . With
intraven ous administ ra tion of haloperidol, th e onset of effec t was wit hin thir ty
minut es. They reported high er efficacy via the int ravenou s route a nd fou nd no
contra ind ica t ions to us ing halope rid ol to treat ag itation in child re n.
Droperidol
Droperidol is a no t he r butyrophen on e neuroleptic th a t has a lso been used
success fully to treat delirium in adults (26,2 7). It is ava ilable for int ra muscula r or
intravenous administration (17). Compared to haloperid ol , it has a more rap id onset
of action, is more seda ting and is more apt to ca use hypot en sion (9,26) . It s use to treat
delirium in th e pediatric population ha s not been reported. However, droperi dol has
been studied for th e managem ent of acute ag ita t ion and aggression in child re n and
adolescen ts .Joshi et a l. (28) reported use of intramuscul ar d rop eridol in a child re n's
inpatient unit to contro l ext re me aggre ss ion a nd violent beh avior s. Over a period of
three yea rs, twenty-six child re n (mean age 01'9. 14) received a one ti me dose (except
two boys who were refract ory after 30 minutes a nd required another dose) of
droperidol to induce sedat ion. The a mo unt of droperidol used , in th e child re n, was
based on body weight: < 75 Ibs. = If! cc; 75 to 125 Ibs. = Y2 cc; 125 to 150 Ibs. = % cc;
> 150 Ibs. = Icc a nd th e mean dose used was 0.437 cc ( Icc = 2.5 mg) . The use of
d roperidol was deemed efficac ious and produced only mild EPS in two of th e child ren .
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The e me rgence of th e new a typica l a nt ipsychot ics has a llowed a greater arma-
men t of pharmacological choices in treating many psychiatric condit ions in chi ldr en.
The new medications have shown ben efit without some of th e extrapyramidal side
effec ts of th e conve nt ional antipsychotics (29-31). The atypical a n t ipsychotics have
been used in child re n and adolescents in cases of schizophreni a (32,33), autism (34),
a nd pervasive developmental disorder (35).
Dosing regimens of the a typi ca l antipsychotics in child re n and ado lescents vary
in th e lit erat ure . Rispe ridone and olanzapine are on ly adm iniste red enterally.
Rispe ridone was FDA approved in 1993 wit h a dosing range of 2 to 16 mg/d ay (17). In
child re n wit h psyc hot ic disorders, t he opt imal clin ica l response was found a t a mean
da ily dose of 5.93 mg (32) . In au tism, response was with a mean dose of 1.3 mg/d ay
(34) . A study of chi ldren a nd ado lescents with pervasive developmenta l disord er
showed im provement of sym ptoms wit h a mea n dose of 2.7 rug/day (35). The FDA
a pproved ola nzapine in 1996 wit h a dosing ra nge of 5 to 20 rug/day (17). In adults,
ola nzapine has been found to poss es a ntipsychotic properties with a n optimal dosing
range of 2.5 to 15 mg/d ay (30). O lanzapine has not been exte nsively stud ied in
child ren, however, a pilot study of childhood-onset schizophre nia showed efficacy at a
mean dos e of 17.5 rug/day (36). Also a study of child re n, adol escen ts a nd adults with
pervasive developmental disorders showed clinica l improvem ent with a mean dose of
7.8 mg/day (37).
The lit erature does not document man y shor t-te rm contra ind ica t ions of the
newer antipsychotics in child re n and adolescents. Rispe ridone has been shown to
cause mi ld sedation and EPS in a popu lation of adolescents with schizophre nia, with
th e expre ssion of EPS inversely proportionate to th e rate of titration of the risperi-
don e (32). There has been a case report of olanzapine (dosed 7.5 mg/d ay ove r a two to
three week period) inducing mania in a six teen year old male (38) . Also, as with th e
typica l an tipsychotics, there is a ris k of NMS in th e newer a ntipsychotics. Sharma et
al. (39) report of risperidone-in du ced NMS in an ad olescent mal e.
T here have been no syst ematic st udies of the efficacy of treating delir ium in
chi ld ren or adults with the new atypical antipsychotics. However Sipahimalani and
Masand (40) report of a sixty year old male and a fourte en yea r old mal e in whom
deli riu m was successfully t reated with low doses of risperidon c. The adol escen t
responded to I mg of risperid on e a t bed time without side effec ts.
ADJUNCT MEDICATIONS
T he a nt ipsychotic med ications are conside re d efficacious in treating delirium
(4 1). Polyph a rmacy has be en discouraged in child re n (42) . Also, iatrogeni c indu ced
delirium is common. However a few medi cin es hav e been used to au gm ent ant ipsy-
chot ics in trea ting deli rium a nd th ere may be cases where adjunctiv e medicin e is
deemed ap propriate .
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populat ion, th e use of ha loperidol with slow titration to a n efficacious dose would
see m to be th e logica l first lin e approach in treating delirium. If a deli rious child with
ava ilable intravenous access were hospitalized , th en in traven ous route wou ld be
recommended du e to the rapid onset of ac tion and th e lower incidence of EPS. If th e
child does not a lready have intraven ous access, clinician judgement wou ld dict at e if
th e seve rity of symptoms of th e delirium require rapid infu sion of med icin e. The need
for EKG monitoring, with intraven ou s butyrophen on e neurolep tic adm inistration in
child re n and adolesce n ts , is qu esti on abl e. However, we recom men d a conse rva t ive
approach with baseline EKG acquisit ion followed by ca rdiac monitoring or dai ly QTc
interval testing. If th e QTc interval incr eases 25% ove r baseline, then the neurol eptic
dose should be d iscont inued or lowered. The clinical use of d rop eridol in chi ldren is
not as well investigated compare d to ha loperidol. Haloperidol has a longer history of
use in th e ped ia t ric population, however we conside r droperidol an adequate a lte rn a-
tive.
T he re has on ly been on e case report of an atypica l a ntipsycho tic (r isperido ne)
used for th e treatment of delir ium in an adolescent. Atypical a n tipsyc ho tics have
shown efficacy in t rea t ing a number of psychiatric condit ions in child re n and
adolescents, wit h minimal short-te rm sid e effec ts . Controlled studies of the at ypical
antipsychotics in treating delirium are warranted to es tablish th eir efficacy.
These recommendation s a re based on ass umptions from adult populations a nd
th e lim it ed data available pertaining to child re n a nd ado lesc en ts . This prot ocol is not
meant for adheren ce as a protocol prop osed from controlled st udy; rat her it is
proposed as template for further study a nd to suffice as ot her tec hniqu es a nd
managem ent are postulat ed. The lack of dat a a nd sys tematic a na lysis in th e lit era-
ture pertaining to th e treatment of delirium in child ren a nd ado lesc ents dem on-
stra tes an ac ute need for st ruc ture d research in this area.
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